SURGE

1 known investors

SURGE develops a biodegradable hydrogel, based on research at Harvard Medical School, that is injected at the site of surgical tumor resection to locally extend the release of cancer immunotherapy. The therapy aims to prevent post-surgical cancer recurrence and metastasis in patients undergoing surgery for solid tumors.